Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice

(2013) V. K. Ridaura et al.   SCIENCE

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Soluble CD163: a biomarker linking macrophages and insulin resistance

(2012) T. Parkner et al.   DIABETOLOGIA

Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and Metabolic Disorder through Regulatory Cytokine Production

(2012) Lydia Lynch et al.   IMMUNITY

Effect of Exenatide on Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus

(2011) Jin-dan Wu et al.   Diabetes Technology & Therapeutics

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

(2011) A. E. Hogan et al.   DIABETOLOGIA

Exenatide Exerts a Potent Antiinflammatory Effect

(2011) Ajay Chaudhuri et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Defining macrophage phenotype and function in adipose tissue

(2011) Elise Dalmas et al.   TRENDS IN IMMUNOLOGY

RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

(2010) Y. Hattori et al.   DIABETOLOGIA

Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese Mice

(2009) S. Fujisaka et al.   DIABETES